pharmaphorum March 24, 2025
Augustine Therapeutics has raised €78 million ($85 million) in first-round funding for a pipeline headed by a candidate for the inherited neurological disorder Charcot-Marie-Tooth (CMT).
The Leven, Belgium-based biotech has built its business around a series of inhibitors of the HDAC6 enzyme, which is implicated in various neuromuscular, neurodegenerative, and cardio-metabolic diseases.
HDAC inhibitors are already on the market for cancer and some other indications – including Duchenne muscular dystrophy. However, the development of selective HDAC6 inhibitors for cancer has been plagued by limited clinical efficacy, acquired resistance to the drugs, and safety issues resulting from the blockade of beneficial, non-enzymatic functions of the protein.
Augustine believes its “next-generation” cytosolic HDAC6 inhibitors avoid the limitations of earlier drugs, while its...
Today's Sponsors
Today's Sponsor